I'm LongbridgeAI, I can summarize articles.Med Tech segment delivered double-digit growth for the seventh consecutive quarter, driving full-year sales up 18.4% and supporting positive adjusted EBITDA. Gross margin improved to 54.6% for the year, and the company ended with $53.9 million in cash and no debt.Original document: AngioDynamics, Inc. [ANGO] SEC 8-K Current Report — Jul. 14 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Med Tech segment delivered double-digit growth for the seventh consecutive quarter, driving full-year sales up 18.4% and supporting positive adjusted EBITDA. Gross margin improved to 54.6% for the year, and the company ended with $53.9 million in cash and no debt.
Original document: AngioDynamics, Inc. [ANGO] SEC 8-K Current Report — Jul. 14 2026